Healthcare Human Factors

humanfactors.ca

Healthcare Human Factors is the largest Human Factors team dedicated to healthcare internationally. Acting as consultants, researchers, designers and evaluators, we are setting standards and developing best practices for human factors in healthcare, leading cultural change and making an impact locally and worldwide. Located within one of the largest academic health science centres in the world at University Health Network, we are embedded in the healthcare setting with access to clinical users and patients that we design, test and create for. We have state-of-the-art usability testing facilities geared for healthcare and attract private and public sector clients including hospitals, the Ministry of Health and Long-Term Care (MOHLTC), Ontario Medical Association (OMA), and Canada Health Infoway (CHI).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

news image

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More

Medical

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

news image

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

news image

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More

Medical

ARUNA BIO ADVANCES THERAPEUTIC DEVELOPMENT FOR TRAUMATIC BRAIN INJURY

Aruna Bio | June 01, 2022

news image

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...

Read More
news image

BICYCLE AND GENENTECH FORGE IMMUNO-ONCOLOGY COLLABORATION WORTH UP TO $1.7 BILLION

BioSpace | February 25, 2020

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-onc...

Read More
news image

Medical

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More
news image

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More
news image

Medical

ARUNA BIO ADVANCES THERAPEUTIC DEVELOPMENT FOR TRAUMATIC BRAIN INJURY

Aruna Bio | June 01, 2022

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us